Compare Delta Air Lines, Inc. (DAL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Zoetis Inc — how do they compare? Delta Air Lines, Inc. trades at $80.1 (market cap $54.02B), while Zoetis Inc trades at $73.5 (market cap $30.20B). The key difference: Delta Air Lines, Inc. is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Zoetis Inc for 70 Days on average.
| DAL | ZTS | |
|---|---|---|
Market Cap | $54.02B | $30.20B |
Volume | 9,632,845 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $93.66 | $147.53 |
52-Week Low | $55.65 | $69.09 |
Typical Hold Time | 97 Days | 70 Days |
Enterprise Value | $69.34B | $37.76B |
Dividend Yield | 1.05% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters and maintains solid profitability with 5.78% net margin and 20.12% ROE. Recent news highlights competitive pressures from United and American Airlines' customer poaching efforts and Elon Musk's criticism over Delta's Wi-Fi provider choice.
DAL presents a compelling value opportunity with a P/E of 13.62 below industry averages and strong analyst consensus (82% buy ratings) targeting $103.36. However, rising fuel costs, competitive threats to premium customers, and bearish technical indicators create near-term headwinds. The upcoming Q3 earnings report on October 9 will be crucial for validating the company's margin resilience.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
